These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38548875)

  • 1. Implementation of a randomized mobile-technology lifestyle program in individuals with nonalcoholic fatty liver disease.
    Tincopa MA; Patel N; Shahab A; Asefa H; Lok AS
    Sci Rep; 2024 Mar; 14(1):7452. PubMed ID: 38548875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a Pilot Structured Mobile Technology Based Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease.
    Tincopa MA; Lyden A; Wong J; Jackson EA; Richardson C; Lok AS
    Dig Dis Sci; 2022 Feb; 67(2):481-491. PubMed ID: 33939147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
    Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When the liver gets stiff, the tough get moving.
    Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
    J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Performance of Transient Elastography With Comparison to Quantitative Magnetic Resonance Imaging, Ultrasound, and Biopsy in Children and Adolescents With Known or Suspected Fatty Liver Disease.
    P V Alves V; T Trout A; Dewit M; Mouzaki M; Arce-Clachar AC; S Bramlage K; R Dillman J; A Xanthakos S
    Child Obes; 2023 Oct; 19(7):461-469. PubMed ID: 36269577
    [No Abstract]   [Full Text] [Related]  

  • 6. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
    J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound.
    Ding Y; Jiang L; Wang Q; Zhao W; Zhou X; Lu J; Tian T; Yu C; Xu X; Guo W; Zhang Q; Song C
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101951. PubMed ID: 35605893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
    Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
    Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease.
    Blank V; Petroff D; Boehlig A; Heinze A; Karlas T; Berg T; Wiegand J
    Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):686-692. PubMed ID: 35102112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobile App-Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial.
    Kwon OY; Lee MK; Lee HW; Kim H; Lee JS; Jang Y
    J Med Internet Res; 2024 Feb; 26():e49839. PubMed ID: 38358794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Knowledge, Health-Related Quality of Life, and Lifestyle Behavior Change in Patients with Nonalcoholic Fatty Liver Disease: Impact of an Educational Intervention.
    Glass L; Asefa H; Volk M; Lok AS; Tincopa MA
    Dig Dis Sci; 2022 Jun; 67(6):2123-2133. PubMed ID: 34043121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
    J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.
    Buzzetti E; Linden A; Best LM; Madden AM; Roberts D; Chase TJG; Freeman SC; Cooper NJ; Sutton AJ; Fritche D; Milne EJ; Wright K; Pavlov CS; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2021 Jun; 6(6):CD013156. PubMed ID: 34114650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
    Lefere S; Dupont E; De Guchtenaere A; Van Biervliet S; Vande Velde S; Verhelst X; Devisscher L; Van Vlierberghe H; Geerts A; De Bruyne R
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2317-2326.e4. PubMed ID: 34871812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Sangha K; Chang ST; Cheung R; Deshpande VS
    Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
    Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
    AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.